Search results for "combinations"

showing 10 items of 204 documents

Combined oral prolonged-release oxycodone and naloxone in chronic pain management

2013

Introduction: The use of opioids is associated with unwanted adverse effects, particularly opioid-induced constipation (OIC). The adverse effects of opioids on gastrointestinal function are mediated by the interaction with opioid receptors in the gastrointestinal tract. The most common drugs used for relieving OIC are laxatives, which do not address the opioid receptor-mediated bowel dysfunction and do not provide sufficient relief. Areas covered: This paper discusses the role of a combination of prolongedrelease formulation of oxycodone (OX) and naloxone (N) in the prevention and management of OIC, reporting efficacy and safety outcome of controlled studies. In a therapeutic area of great …

medicine.drug_classSettore MED/41 - Anestesiologiacancer pain chronic pain opioid-antagonist opioids oxycodone--naloxone combinationNaloxonemedicineHumansPharmacology (medical)Adverse effectPharmacologybusiness.industryNaloxoneChronic painGeneral Medicinemedicine.diseaseAnalgesics OpioidDrug CombinationsTreatment OutcomeOpioidAnesthesiaDelayed-Action PreparationsChronic PainGastrointestinal functionbusinessCancer painOxycodoneOpioid antagonistOxycodonemedicine.drug
researchProduct

Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage.

2014

International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studi…

medicine.medical_specialtyCombination therapyAsthma exacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionateAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerAsthma controlFluticasone propionate/formoterolForced Expiratory VolumeFormoterol FumarateInternal MedicineMedicineHumansAnti-Asthmatic AgentsAsthma exacerbationsParticle SizeIntensive care medicineAsthmaFluticasonebusiness.industryInhalerNebulizers and VaporizersFixed-combination therapyAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhaler; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations; Ethanolamines; Fluticasone; Forced Expiratory Volume; Formoterol Fumarate; Humans; Nebulizers and Vaporizers; Particle Size; Quality of Life; Treatment Outcomemedicine.diseaseSingle-aerosol inhalerAsthmaBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilityAsthma control Asthma exacerbations Fixed-combination therapy Fluticasone propionate/formoterol Single-aerosol inhalerEthanolaminesAnesthesiaAsthma exacerbations; Asthma control; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerQuality of LifeFluticasoneFormoterol FumarateFormoterolbusinessmedicine.drugEuropean journal of internal medicine
researchProduct

Impact of COVID-19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV-HF-SIRIO 6 study)

2022

Abstract Aims The coronavirus disease‐2019 (COVID‐19) pandemic has changed the landscape of medical care delivery worldwide. We aimed to assess the influence of COVID‐19 pandemic on hospital admissions and in‐hospital mortality rate in patients with acute heart failure (AHF) in a retrospective, multicentre study. Methods and results From 1 January 2019 to 31 December 2020, a total of 101 433 patients were hospitalized in 24 Cardiology Departments in Poland. The number of patients admitted due to AHF decreased by 23.4% from 9853 in 2019 to 7546 in 2020 (P < 0.001). We noted a significant reduction of self‐referrals in the times of COVID‐19 pandemic accounting 27.8% (P < 0.001), with increase…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Heart failureMedical careLevodopaCOVID‐19Internal medicinePandemicmedicineHumansDiseases of the circulatory (Cardiovascular) systemIn patientPandemicsRetrospective StudiesSARS-CoV-2business.industryMortality rateCarbidopaCOVID-19Original Articlesmedicine.diseaseIn‐hospital mortalityHospitalizationDrug CombinationsIn-hospital mortalityRC666-701Heart failureConcomitantAcute DiseaseOriginal ArticleCardiology and Cardiovascular MedicinebusinessHospital stayESC heart failure
researchProduct

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting

2019

Real-life data confirming the favourable renal outcome in patients with heart failure (HF) treated with Sacubitril/Valsartan, previously found in several trials (RCTs), are still scant. We evaluated the renal effects of Sacubitril/Valsartan in a real-life sample of HF patients. Observational analysis of 54 consecutive outpatients affected by HF with reduced ejection fraction (HFrEF) and clinical indication for Sacubitril/Valsartan. Patients were evaluated at baseline (T0) and after six (T6) and twelve (T12) months after initiating Sacubitril/Valsartan and compared with a group of 30 historical controls. Mean age: 65.5 ± 11.7 years. Older patients: 29 (53.7%). Mean baseline estimated glomeru…

medicine.medical_specialtyMEDLINETetrazolesHeart failureLifeInternal MedicinemedicineHumansKidney dysfunctionSacubitril-ValsartanIntensive care medicinebusiness.industryAminobutyratesBiphenyl CompoundsFollow up studiesSacubitril/Valsartanmedicine.diseaseIm - OriginalDrug CombinationsValsartanHeart failureBlood pressureEmergency MedicineValsartanbusinessSacubitril ValsartanFollow-Up StudiesRenal functionmedicine.drug
researchProduct

Impact of donor-recipient age on cardiac transplant survival. Subanalysis of the Spanish Heart Transplant Registry.

2020

[Abstract] Introduction and objectives. The age of heart transplant recipients and donors is progressively increasing. It is likely that not all donor-recipient age combinations have the same impact on mortality. The objective of this work was to compare survival in transplant recipients according to donor-recipient age combinations. Methods. We performed a retrospective analysis of transplants performed between 1 January 1993 and 31 December 2017 in the Spanish Heart Transplant Registry. Pediatric transplants, retransplants and combined transplants were excluded (6505 transplants included). Four groups were considered: a) donor < 50 years for recipient < 65 years; b) donor < 50 years for r…

medicine.medical_specialtyPrognostic factorTrasplante cardiacoMultivariate analysisSurvivalCombinaciones de edad de donante y receptor Donor age Donor/recipient age combinations Edad del donante Edad del receptor Heart transplant Recipient age Supervivencia Survival Trasplante cardiacoEnfermedad cardiovascularDonor/recipient age combinationsRecipient age030204 cardiovascular system & hematologyDonor age03 medical and health sciences0302 clinical medicineInternal medicineRetrospective analysisEdad del receptorMedicineHumansTrasplante de corazónRegistriesChildRetrospective StudiesSupervivenciabusiness.industryEdad del donanteGraft SurvivalAge FactorsCombinaciones de edad de donante y receptorGeneral MedicineTissue DonorsTransplant RecipientsTrasplante de órganosDatos estadísticosHeart TransplantationHeart transplantSupervivencia tisularbusinessMedian survival
researchProduct

Caffeine increases the expression of cystatin SN in human submandibular acinar-like HSG cells

2013

The study aimed at evaluating in vitro the effect of caffeine on expression of cystatin SN, a potential marker of sensitivity to bitterness in humans.Differentiation of human submandibular gland (HSG) cells was induced by culturing cells on Matrigel. Caffeine cytotoxicity was assessed over 3 days by the Resazurin test. Finally, effects of 5, 50 and 100μM caffeine exposure on cystatin SN expression were explored over 3 days by ELISA.At concentrations relevant to human adult plasma levels (5, 50 and 100μM), caffeine did not affect cell viability whether cells were differentiated or not. Cystatin SN levels were overall higher in differentiated cells and increased with time in both conditions. …

medicine.medical_specialtySalivaCellular differentiationeducationCell Culture TechniquesEnzyme-Linked Immunosorbent Assay[SDV.TOX.TCA]Life Sciences [q-bio]/Toxicology/Toxicology and food chain03 medical and health scienceschemistry.chemical_compound0302 clinical medicinestomatognathic systemInternal medicineCaffeinemedicineHumansViability assaySalivaGeneral DentistryBitterness030304 developmental biology0303 health sciencesMatrigelSubmandibular glandChemistryCell BiologyGeneral MedicineSubmandibular glandIn vitroDrug CombinationsEndocrinologymedicine.anatomical_structureOtorhinolaryngologyCell culture030220 oncology & carcinogenesisSalivary CystatinsProteoglycansHSG cell lineCollagenLamininCaffeine
researchProduct

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension deliver…

2018

COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are central to the maintenance treatment of patients with COPD. Clinical studies have demonstrated that combined LAMA + LABA therapies improve efficacy while retaining a safety profile similar to LAMA or LABA alone. This has led to the development of several LAMA/LABA fixed-dose combination (FDC) therapies, which provide patients with the convenience of two active compounds in a single inhaler. GFF MDI (Bevespi Aerosphere®) is an FDC of glycopyrrolate/formote…

medicine.medical_specialtymedicine.drug_classDrug CompoundingFixed-dose combinationMuscarinic AntagonistsPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineFormoterol FumarateBronchodilatorAdministration InhalationmedicineHumans030212 general & internal medicineIntensive care medicineAdrenergic beta-2 Receptor AgonistsGlycopyrrolateCOPDbiologybusiness.industryInhalerGeneral MedicineLamamedicine.diseasebiology.organism_classificationGlycopyrrolateMetered-dose inhalerBronchodilator AgentsDrug CombinationsTreatment Outcome030228 respiratory systemFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simula…

2020

Omar S Usmani,1 Nicola Scichilone,2 Benjamin Mignot,3 Dennis Belmans,3 Cedric Van Holsbeke,3 Jan De Backer,3 Roberta De Maria,4 Erika Cuoghi,4 Eva Topole,4 George Georges4 1Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK; 2PROMISE Department of Medicine, University of Palermo, Palermo, Italy; 3FLUIDDA, Kontich, Belgium; 4Chiesi Farmaceutici, SpA, Parma, ItalyCorrespondence: George GeorgesChiesi USA Inc., 175 Regency Woods Place, Ste. 600, Cary, NC 27518, USATel +1 (919) 678 6611 x1536Email george.georges@chiesi.comIntroduction: There is a clear correlation between small airways dysfunction and poor clinical outcomes in patients with chronic obstructiv…

medicine.medical_specialtymedicine.drug_classRespiratory SystemUrologyInternational Journal of Chronic Obstructive Pulmonary DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratoriotomographyDry powder inhalers Inhaled corticosteroid Long-acting beta2 agonist Long-acting muscarinic antagonist Metered dose inhalers Tomography X-ray computedinhaled corticosteroidFluticasone propionatePulmonary Disease Chronic Obstructivechemistry.chemical_compoundFormoterol FumarateBronchodilatorAdministration InhalationmedicineHumanslong-acting muscarinic antagonistComputer SimulationGlycopyrronium bromideRespiratory systemmetered dose inhalers1102 Cardiorespiratory Medicine and HaematologyOriginal Researchx-ray computedlcsh:RC705-779COPDScience & TechnologyInhalationbusiness.industrydry powder inhalersGeneral Medicinelcsh:Diseases of the respiratory systemrespiratory systemmedicine.diseaseBronchodilator AgentsDrug CombinationschemistryCorticosteroidVilanterolbusinessLife Sciences & Biomedicinelong-acting beta2 agonistmedicine.drugInternational Journal of COPD
researchProduct

Granulocyte-macrophage colony-stimulating factor (CSF) and multilineage CSF recruit human monocytes to express granulocyte CSF

1989

Abstract We assessed the capacity of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and multilineage (Multi)-CSF to induce release of granulocyte-CSF (G-CSF) by highly purified peripheral blood monocyte (Mo) preparations. Our results reveal that GM-CSF and Multi-CSF, either alone or in a synergistic concert, activate Mo to transcribe G-CSF messenger (m) RNA and release biologically active G- CSF protein into their culture supernatants. G-CSF had no regulatory effect on Mo expression of cytoplasmic G-CSF mRNA levels and G-CSF protein secretion by itself. These differential actions of CSFs provide further insight into self-regulatory mechanisms within the growth f…

medicine.medical_treatmentImmunologyGranulocyteBiologyBiochemistryMonocyteslaw.inventionColony-Stimulating FactorslawmedicineHumansRNA MessengerGrowth SubstancesCells CulturedCSF albuminCell-Free SystemGrowth factorGranulocyte-Macrophage Colony-Stimulating FactorRNABiological activityCell BiologyHematologyMolecular biologyRecombinant ProteinsDrug CombinationsGranulocyte macrophage colony-stimulating factorSecretory proteinmedicine.anatomical_structureImmunologyRecombinant DNAGranulocytesmedicine.drugBlood
researchProduct

Extracellular matrix regulation of PTHrP and PTH/PTHrP receptor in a human breast cancer cell line

1999

AbstractIt was previously reported that 8701-BC breast cancer cells express the gene for parathyroid hormone-related peptide (PTHrP) and its cognate receptor (PTHrP-R), and release immunoreactive PTHrP in the extracellular medium; it was also found that PTHrP, in turn, exerts a role on the proliferative and invasive behavior in vitro of the same cell line. On the other hand, evidence has been produced that adhesion of 8701-BC cells onto different collagen substrates influences in various ways a number of phenotypic expressions, such as cell growth, motility, invasion of reconstituted basement membrane and production of lytic enzymes of the extracellular matrix (ECM). In light of these previ…

musculoskeletal diseasesmedicine.medical_specialtyParathyroid hormone-related peptideStromal cellRNA SplicingCellular differentiationBiophysicsBreast NeoplasmsBiologyPolymerase Chain ReactionBiochemistryExtracellular matrixBreast cancerStructural BiologyLamininInternal medicineGene expressionTumor Cells CulturedGeneticsmedicineExtracellularHumansParathyroid hormone-related peptide receptorMolecular BiologyReceptor Parathyroid Hormone Type 1Basement membraneParathyroid Hormone-Related ProteinProteinsCell DifferentiationCell Biologymusculoskeletal systemExtracellular MatrixNeoplasm ProteinsCell biologyGene Expression Regulation NeoplasticDrug CombinationsEndocrinologymedicine.anatomical_structureCell culturebiology.proteinReceptors Parathyroid HormoneProteoglycansGene expressionCollagenLamininhormones hormone substitutes and hormone antagonistsFEBS Letters
researchProduct